ALR Technologies SG Ltd.
ALR Technologies SG Ltd. is a Singapore-based medical technology company focused on glucose-monitoring and digital diabetes-management solutions. Its business centers on connected continuous glucose monitoring products and related software platforms for people managing diabetes, with activity that includes commercialization across North American and other international markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueWearable glucose-monitoring products and related digital tools for diabetes management.
GluCurve Pet CGM offerings designed for glucose monitoring in animals.
Connected software, tracking, and data services that support glucose-monitoring workflows.
Customers
The company serves patients and caregivers who need glucose monitoring and digital diabetes-management tools, with use cases spanning both human and pet health. Its products are also relevant to clinicians, distributors, and channel partners that help bring monitoring solutions to end users. The launch of pet CGM indicates an additional veterinary end market alongside traditional diabetes-care users.
Buy CGM devices and related software to track glucose trends and support day-to-day management.
Use connected monitoring tools to observe readings and manage diabetes for another person.
Purchases GluCurve Pet CGM products for glucose monitoring in companion animals.
Adopt the platform to support monitoring, review data, and manage patient workflows.
Buy products for channel distribution and market expansion in target geographies.
Strategy
The company’s strategy appears centered on commercializing its glucose-monitoring platform and extending it into adjacent use cases such as pet CGM. Launching products in new markets suggests a priority on geographic expansion and channel development rather than a single-home-market model. Building a connected device-and-software offering can increase customer stickiness and create a broader digital health platform around monitoring data.
Broader market access increases the installed base and reduces reliance on a single geography.
Software and data services can strengthen recurring customer engagement around the device.
Adjacency to pet health can open a differentiated niche and broaden the addressable market.
Geography
2025ALR Technologies SG Ltd. is headquartered in Singapore, while the available filing shows principal executive-office activity in Singapore and disclosure to U.S. markets through SEC reporting. The company’s business is oriented toward international commercialization, including a stated product launch in Canada, which suggests a North American market focus for certain products. Its geography matters because medical-device commercialization, regulatory approvals, and channel access can differ significantly by country.
Risks
The business depends on regulatory acceptance, product performance, and channel execution in a highly competitive medical-device market. Because its products span connected hardware and software, it also faces risks around adoption, reimbursement, supply continuity, and cross-border commercialization. Expansion into new geographies and new end markets can create additional execution risk if product claims, approvals, or distribution are delayed.
- Competitive pressureImpact: HighLikelihood: High
The diabetes-monitoring market is crowded and larger incumbents can outspend on distribution and product development.
Exposure: CGM devices and digital diabetes tools
- Regulatory approval and compliance riskImpact: HighLikelihood: Medium
Glucose-monitoring devices must meet country-specific medical-device rules before commercialization.
Exposure: New market launches such as Canada
- Commercial adoption riskImpact: HighLikelihood: Medium
Customers may delay switching to a new CGM platform if accuracy, usability, or support are not compelling.
Exposure: Human CGM and pet CGM products
- Execution risk in new geographiesImpact: MediumLikelihood: Medium
Launching in new countries requires local regulatory, logistics, and channel capabilities.
Exposure: Canada and other international markets
Accounting
Judgemental itemsDevice sales, software access, and bundled offerings may have different timing and allocation rules.
Impact: Can shift reported revenue between periods
Medical-device inventory can become obsolete if product specs, approvals, or demand change.
Impact: Can affect gross profit and working capital
Product platforms and launch-related intangibles may need write-downs if commercialization lags.
Impact: Can create non-cash charges
Similar listed companies
Publicly listed companies with a comparable business focus.
Glucotrack, Inc.
GCTK · Surgical & Medical Instruments & Apparatus
Senseonics Holdings, Inc.
SENS · Industrial Instruments For Measurement, Display, and Control
Mobile-health Network Solutions
MNDR · Services-Prepackaged Software
Mobile-health Network Solutions is a Singapore-headquartered digital health company that operates an AI-enabled telemedicine platform and related virtual-care software.
BGM Group Ltd.
BGM · Pharmaceutical Preparations
BGM Group Ltd is a Cayman Islands holding company with operating businesses primarily conducted through subsidiaries and variable interest entities in mainland China.
Actuate Therapeutics, Inc
ACTU · Pharmaceutical Preparations
Profusa, Inc.
NVACW · Surgical & Medical Instruments & Apparatus
Last updated: 28/09/2026